Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry
- PMID: 24939944
- DOI: 10.1093/ehjci/jeu114
Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry
Abstract
Aim: The aim of this study was to evaluate the association of baseline tricuspid regurgitation (TR) on the outcomes after percutaneous mitral valve repair (PMVR) with the MitraClip system.
Methods and results: Data from 146 consecutive patients with functional mitral regurgitation (MR) were obtained. Two different groups, dichotomized according to the degree of pre-procedural TR (moderate/severe, n = 47 and none/mild, n = 99), had their clinical and echocardiographic outcomes through 12-month compared. At 30-day, the primary safety endpoint was significantly higher in moderate/severe TR compared with none/mild TR (10.6 vs. 2.0%, P = 0.035). Marked reduction in MR grades observed post-procedure were maintained through 12 months. Although NYHA functional class significantly improved in both groups compared with baseline, it was impaired in moderate/severe TR compared with the none/mild TR group (NYHA > II at 30 day: 33.3 vs. 9.2%, P < 0.001; at 1 year: 38.5 vs. 12.3%, respectively, P = 0.006). Left ventricle reverse remodelling and ejection fraction improvement were revealed in both groups. The primary efficacy endpoint at 12-month determined by freedom from death, surgery for mitral valve dysfunction, or grade ≥ 3+ MR was comparable between groups, but combined death and re-hospitalization for heart failure rates were higher in the moderate/severe TR group. Multivariable Cox regression analysis demonstrated that baseline moderate/severe TR and chronic kidney disease were independent predictors of this combined endpoint.
Conclusions: Although PMVR with MitraClip led to improvement in MR, TR, and NYHA functional class in patients with baseline moderate/severe TR, the primary safety endpoint at 30-day was impaired, while moderate/severe TR independently predicted death and re-hospitalization for heart failure at 12-month.
Keywords: MitraClip; Mitral regurgitation; Percutaneous mitral valve repair; Tricuspid regurgitation.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com.
Similar articles
-
Post-procedural tricuspid regurgitation predicts long-term survival in patients undergoing percutaneous mitral valve repair.J Cardiol. 2019 Dec;74(6):524-531. doi: 10.1016/j.jjcc.2019.05.009. Epub 2019 Jun 22. J Cardiol. 2019. PMID: 31239089
-
Gender-related clinical and echocardiographic outcomes at 30-day and 12-month follow up after MitraClip implantation in the GRASP registry.Catheter Cardiovasc Interv. 2015 Apr;85(5):889-97. doi: 10.1002/ccd.25715. Epub 2014 Nov 10. Catheter Cardiovasc Interv. 2015. PMID: 25367550
-
Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry.JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):74-82. doi: 10.1016/j.jcin.2014.07.024. Epub 2014 Dec 10. JACC Cardiovasc Interv. 2015. PMID: 25499300
-
Clinical outcomes of percutaneous mitral valve repair with MitraClip for the management of functional mitral regurgitation.Catheter Cardiovasc Interv. 2019 Nov 15;94(6):820-826. doi: 10.1002/ccd.28203. Epub 2019 Apr 1. Catheter Cardiovasc Interv. 2019. PMID: 30938045 Review.
-
Which patient undergoing mitral valve surgery should also have the tricuspid repair?Interact Cardiovasc Thorac Surg. 2009 Dec;9(6):1009-20. doi: 10.1510/icvts.2009.217570. Epub 2009 Sep 24. Interact Cardiovasc Thorac Surg. 2009. PMID: 19778956 Review.
Cited by
-
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality.Eur J Heart Fail. 2022 Nov;24(11):2175-2184. doi: 10.1002/ejhf.2637. Epub 2022 Aug 16. Eur J Heart Fail. 2022. PMID: 36482160 Free PMC article.
-
Transcatheter Mitral Valve Therapy: Defining the Patient Who Will Benefit.Curr Cardiol Rep. 2018 Sep 12;20(11):107. doi: 10.1007/s11886-018-1058-8. Curr Cardiol Rep. 2018. PMID: 30209638 Review.
-
A Practical Approach to Combined Transcatheter Mitral and Tricuspid Valve Intervention.Front Cardiovasc Med. 2021 Oct 13;8:706123. doi: 10.3389/fcvm.2021.706123. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34722653 Free PMC article. Review.
-
Interrelationship Between Kidney Function and Percutaneous Mitral Valve Interventions: A Comprehensive Review.Curr Cardiol Rev. 2019;15(2):76-82. doi: 10.2174/1573403X14666181024155247. Curr Cardiol Rev. 2019. PMID: 30360746 Free PMC article. Review.
-
Comparative analysis of MitraClip/TriClip and PASCAL in transcatheter tricuspid valve repair for tricuspid regurgitation: a systematic review and meta-analysis.BMC Cardiovasc Disord. 2024 Oct 14;24(1):557. doi: 10.1186/s12872-024-04201-6. BMC Cardiovasc Disord. 2024. PMID: 39402473 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources